Tender detail

Open-house biologics discount agreements 2025-19 – adalimumab

Summary

The participating health insurers intend to conclude discount agreements for the active substance adalimumab with all suitable pharmaceutical companies. The agreements use uniform terms, involve no individual negotiations and provide no exclusivity. The term is up to 24 months from 1 August 2025 and ends no later than 31 July 2027, regardless of when an agreement is signed.

Reference number
dce5ee6d-bd50-4aa2-9ac6-c73316e1c3fd
Buyer
Country
Germany (DEU)
Procedure
Open procedure
CPV
33600000 Pharmaceutical products
Deadline
2026-12-31
Status
Open
Contract subject
Supplies
Estimated value
Not published
Source
DEU_BKMS

More tender information after sign-in

The public view shows key tender details. Sign in to open official links, documents and AI tender support.